Show simple item record

Authordc.contributor.authorBelaunzarán Zamudio, Pablo 
Authordc.contributor.authorCaro Vega, Yanink 
Authordc.contributor.authorShepherd, Bryan E. 
Authordc.contributor.authorCrabtree Ramírez, Brenda 
Authordc.contributor.authorLuz, Paula M. 
Authordc.contributor.authorGrinsztejn, Beatriz 
Authordc.contributor.authorCesar, Carina 
Authordc.contributor.authorCahn, Pedro 
Authordc.contributor.authorCortés, Claudia 
Authordc.contributor.authorWolff Reyes, Marcelo 
Authordc.contributor.authorPape, Jean W. 
Authordc.contributor.authorPadgett, Denis 
Authordc.contributor.authorGotuzzo, Eduardo 
Authordc.contributor.authorMcGowan, Catherine 
Admission datedc.date.accessioned2019-01-29T15:38:27Z
Available datedc.date.available2019-01-29T15:38:27Z
Publication datedc.date.issued2015
Cita de ítemdc.identifier.citationBulletin of the World Health Organization, Volumen 93, Issue 8, 2018, Pages 529-539
Identifierdc.identifier.issn15640604
Identifierdc.identifier.issn00429686
Identifierdc.identifier.other10.2471/BLT.14.147447
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/161908
Abstractdc.description.abstract© 2015, World Health Organization. All Rights Reserved. Objective To determine the prevalence of adequate monitoring and the costs of measuring CD4+ T-lymphocytes (CD4+ cell) and human immunodeficiency virus (HIV) viral load in people receiving antiretroviral therapy (ART) in seven countries in the WHO Region of the Americas. Methods We obtained retrospective, longitudinal data for 14 476 adults who started a first ART regimen at seven HIV clinics in Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru between 2000 and 2011. We estimated the proportion of 180-day periods with adequate monitoring, which we defined as at least one CD4+ cell count and one viral load measurement. Factors associated with adequate monitoring were analysed using regression methods. The costs of the tests were estimated. Findings The median follow-up time was 50.4 months; the proportion of 180-day periods with adequate CD4+ cell counts was 69% while the proportion with adequate monitoring was 62%. Adequa
Lenguagedc.language.isoen
Publisherdc.publisherWorld Health Organization
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
Sourcedc.sourceBulletin of the World Health Organization
Keywordsdc.subjectPublic Health, Environmental and Occupational Health
Títulodc.titleMonitoring of HIV treatment in seven countries in the WHO region of the Americas Suivi du traitement du VIH dans sept pays de la Région OMS des Amériques Monitoreo del tratamiento del VIH en siete paises de la Region de las Americas de la OMS
Document typedc.typeArtículo de revista
Catalogueruchile.catalogadorSCOPUS
Indexationuchile.indexArtículo de publicación SCOPUS
uchile.cosechauchile.cosechaSI


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile